Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

0.3151
-0.0515-14.05%
Post-market: 0.3059-0.0092-2.92%19:59 EDT
Volume:24.26M
Turnover:7.75M
Market Cap:16.07M
PE:-0.13
High:0.3433
Open:0.3200
Low:0.2974
Close:0.3666
Loading ...

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
07 Mar

Equity Markets Fall as US Layoffs Surge in February

MT Newswires Live
·
07 Mar

Top Midday Gainers

MT Newswires Live
·
07 Mar

Sector Update: Health Care Stocks Retreat Thursday Afternoon

MT Newswires Live
·
07 Mar

Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge

MT Newswires Live
·
06 Mar

BRIEF-Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda

Reuters
·
06 Mar

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients With Lung Cancer

THOMSON REUTERS
·
06 Mar

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire
·
06 Mar

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall

MT Newswires Live
·
05 Mar

Plus Therapeutics sees $15M in gross proceeds from private placement

TIPRANKS
·
05 Mar

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

THOMSON REUTERS
·
05 Mar

Plus Therapeutics granted orphan designation for lung cancer treatment

TIPRANKS
·
01 Mar

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
28 Feb

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients With Leptomeningeal Metastases

THOMSON REUTERS
·
26 Feb

Plus Therapeutics appoints Russell Bradley as president, CNSide

TIPRANKS
·
24 Feb

Plus Therapeutics Announces Leadership Appointments for Its Cnside Diagnostics Subsidiary

THOMSON REUTERS
·
24 Feb

Plus Therapeutics Appoints DR. Michael Rosol as Chief Development Officer

THOMSON REUTERS
·
20 Feb

Plus Therapeutics secures $5.7M financing

TIPRANKS
·
18 Feb

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dow Jones
·
18 Feb